Senhwa Biosciences announces positive data from phase 1/expansion trial of Silmitasertib for basal cell carcinoma treatment: Taipei, Taiwan Thursday, April 3, 2025, 15:00 Hrs [IST ...

Libtayo was approved by the US Food and Drug ... Elsewhere in the field of NSCLC treatments, Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial ...

Libtayo could capture up to $1 billion in sales from the NSCLC category, according to analysts, although additional upside is possible if an ongoing combination study yields positive results.

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in ...

The positive CHMP opinion is supported by data ... which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous ...

Libtayo was originally marketed with Sanofi ... which trials showed brought a very positive 74% remission rate, and the FDA is due to respond by the end of July 2025. Given their previous ...

One patient with Merkel cell carcinoma (MCC) achieved a durable complete response with 15 milligrams per kilogram (mg/kg) solnerstotug and Libtayo (cemiplimab) and remains on treatment at 42 or more ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...